Conference Coverage (AACR)

Phase I Trial of GD3-Lactone-KLH Melanoma Vaccine Presented

Published in Gene Therapy Weekly, May 26th, 1997

Results of a Phase I clinical trial of the GD3-Lactone-KLH conjugate vaccine with the immunological adjuvant QS-21 were presented at the American Association for Cancer Research conference, held April 12-16, 1997, in San Diego, California.

"The significant finding in this study is that for the first time, an immune response against GD3 was observed in all patients vaccinated with our new preparation," reported Dr. Govindaswami Ragupathi during a press briefing.

He explained that the GD3, as well as GD2 and GM2, are gangliosides that belong to a class of carbohydrate antigens and that carbohydrates are the most abundantly expressed antigens on the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry